Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 14/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242524 | 0.89 | KMT2A (0.36) | KMT2AHSD11B1CYP2C9CYP3A4GAA | |
| SCHEMBL3092506 | 0.78 | KMT2A (0.37) | KMT2AHSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL3977195 | 0.77 | KMT2A (0.45) | KMT2AHSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL740950 | 0.76 | KCNA5 (0.31) | KMT2A | |
| SCHEMBL4190391 | 0.75 | KMT2A (0.47) | KMT2AHSD11B1CYP2C9CYP2C19GAA | |
| SCHEMBL14319753 | 0.75 | KMT2A (0.47) | KMT2AHSD11B1CYP2C19GAAMAPK1 | |
| SCHEMBL4181294 | 0.75 | KMT2A (0.47) | KMT2AHSD11B1CYP2C9CYP2C19GAA | |
| SCHEMBL3975085 | 0.74 | KMT2A (0.44) | KMT2AHSD11B1CYP2C19GAAMAPK1 | |
| SCHEMBL13764766 | 0.74 | KMT2A (0.44) | KMT2AHSD11B1CYP2C19GAAMAPK1 | |
| SCHEMBL4179796 | 0.74 | KMT2A (0.44) | KMT2AHSD11B1CYP2C19GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-7842818-B2 | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20100234410-A1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2000467-A9 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DHPS, COASY, NQO2 | KMT2A 2610/4885HSD11B1 849/4885CYP2C9 369/4885 |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DHPS, SQLE, NQO2 | KMT2A 4244/4885HSD11B1 241/4885CYP2C9 128/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | KMT2A 2807/4885HSD11B1 634/4885CYP2C9 357/4885 |
| US-20100234410-A1 | HYDRATE FOR MEDICAL PURPOSES | HTR7, UGT1A7, H1-5 | KMT2A 798/4885HSD11B1 1516/4885CYP2C9 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.